Skip to main content

Table 3 Summary of included economic analyses

From: Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion

Study, country

Form of economic analysis

Treatment

Comparator

Patient population

Model horizon

Taylor et al., 2014 [33] UK

Cost-effectiveness

Ranibizumab

Observation

Patients with ME secondary to CRVO

Lifetime

Eriksson et al., 2014 [29] Sweden

Cost-effectiveness

Aflibercept

Ranibizumab

Patients with ME secondary to CRVO; average starting age 64 years

15 years

Duff et al., 2012 [31] USA

Cost-utility

1) Ranibizumab

1) Dexamethasone intravitreal implant

Patients with ME secondary to CRVO

2 years

2) Dexamethasone intravitreal implant

2) Steroids

Haig et al., 2012 [32] Canada

Cost-utility

Ranibizumab

Observation

Patients (66–68 years) with ME secondary to CRVO

Lifetime

Vincente et al., 2013 [30] Canada

Cost-effectiveness

Dexamethasone intravitreal implant

Observation

Patients with ME and vision loss secondary to CRVO

Lifetime

Hayward et al., 2011 [34] UK

Cost-utility

Dexamethasone intravitreal implant

Observation

Patients with ME secondary to CRVO from GENEVA 008 and 009 clinical trial studies

Lifetime

Kowalski et al., 2011 [35] USA

Cost-utility

Dexamethasone intravitreal implant

Observation

Individual patient-level data were pooled from phase 3 studies of patients with ME following CRVO; mean age 65 years and study-eye visual acuity of 20/80

Lifetime

  1. CRVO central retinal vein occlusion, ME macular edema